What happened with SNDX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Syndax Pharmaceuticals has two FDA-approved medicines on the U.S. market. Revuforj treats eligible patients whose acute leukemia has returned or resisted treatment and carries specified KMT2A or NPM1 genetic changes; the NPM1 indication also requires that patients have no satisfactory alternative treatment. Niktimvo treats eligible patients with chronic graft-versus-host disease after multiple prior systemic treatments have failed.
Most revenue comes from Revuforj, for which Syndax manages sales, marketing and distribution. Niktimvo provides a second substantial source: Syndax co-commercializes it with Incyte in the United States and shares the resulting profits and losses equally. Incyte leads commercialization globally and holds exclusive rights outside the United States, where Syndax is eligible for sales royalties and milestone payments. Syndax also sold Royalty Pharma a right to a portion of U.S. Niktimvo sales in exchange for upfront funding, with total payments capped.
The business depends on government and private insurers covering these medicines, Incyte's work on Niktimvo, and outside suppliers maintaining drug supply. Syndax has no manufacturing facilities of its own and relies on contract manufacturers and Incyte. It may promote the medicines only for approved uses and consistently with their FDA labeling.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Syndax’s results hinge on Revuforj adoption and Niktimvo commercialization with Incyte, while Niktimvo also depends on its underlying license from UCB.
Kura Oncology’s KOMZIFTI competes with Syndax’s Revuforj for adults with relapsed or refractory AML carrying a susceptible NPM1 mutation who have no satisfactory alternative treatment options; both are oral menin inhibitors. Kura’s U.S. KOMZIFTI sales are a concrete measure to watch as this competing treatment gains use.
Syndax depends on Incyte to lead global Niktimvo commercialization and supply product, and the two share U.S. commercialization profits and losses equally. Watch Niktimvo sales alongside production and shared selling costs: Syndax records its half of the resulting profit as collaboration revenue, not half of product sales.
Syndax pays AbbVie milestones and sales royalties for the right to develop and sell its menin-inhibitor assets, so those obligations accompany the business’s progress. AbbVie also markets Venclexta in AML, placing it among the treatments competing with Syndax’s Revuforj.
Johnson & Johnson’s Janssen menin-inhibitor program could challenge Syndax’s Revuforj, making its development progress relevant to Revuforj’s competitive position. This is a competing drug program to watch, rather than a shared revenue stream.
Rigel Pharmaceuticals’ REZLIDHIA and Syndax’s Revuforj both treat relapsed or refractory AML, but their approved mutation-defined patient groups differ. REZLIDHIA serves adults with a susceptible IDH1 mutation, while Revuforj’s AML indication covers patients aged one year or older with a susceptible NPM1 mutation and no satisfactory alternative treatment options, so REZLIDHIA sales are not a like-for-like measure of competition.
SELLAS Life Sciences develops AML treatments that could compete with Syndax’s marketed Revuforj, so AML trial outcomes matter to both businesses. Watch SELLAS’s cancer-drug development results for signs of future competition, rather than treating it as an existing commercial rival.
Incyte Genomics Inc earningsINCY
If Incyte's report discusses Niktimvo sales, supply or shared selling costs, it can show what is shaping the profit share Syndax receives from their collaboration.
If Incyte discloses Niktimvo sales and supply, read sales alongside shared selling costs. Rising sales with supply keeping pace and costs not growing faster would support a larger profit share for Syndax. Weak sales, supply limits or faster-rising costs would constrain that share. Syndax records its share of profit, not half of Niktimvo sales; the conclusion is whether the collaboration is producing more profit for Syndax.
Syndax Pharmaceuticals, Inc. earningsThis company
Syndax's report will show whether sales of its two new medicines and its profit share with Incyte are keeping pace with the costs of selling them.
Keep Revuforj net product revenue separate from Niktimvo collaboration revenue: the latter is Syndax's share of profit, not half of the drug's sales. Growth in both would show that commercialization is expanding for both medicines. If Revuforj revenue stalls, or Niktimvo sales rise without a larger profit share because shared selling costs also rise, growth is not yet translating into better operating returns. The conclusion is whether revenue growth is keeping up with selling and operating costs.
Kura Oncology, Inc. earningsKURA
Kura Oncology's report can show whether U.S. sales of KOMZIFTI are gaining ground against Revuforj for patients with the same mutation-defined form of AML.
Watch Kura's U.S. KOMZIFTI sales. Growth would show that this other oral menin inhibitor is gaining use among patients with the overlapping NPM1-mutated AML indication, potentially sharpening competition for Revuforj. Weak sales would mean less evidence of commercial traction for the rival, not proof of stronger demand for Revuforj. The conclusion is whether a direct competitor is gaining adoption among these patients.
